EMERYVILLE, Calif., January 22, 2026 — Vivani Medical announced that its wholly owned subsidiary Cortigent will present advanced clinical findings on the Orion® Visual Cortical Prosthesis System, an investigational brain implant designed to restore artificial vision, during a scientific poster session at a major neuromodulation meeting. The presentation highlights long-term safety, reliability, and functional outcomes from the Orion Early Feasibility Study, reinforcing Cortigent’s position at the intersection of clinical neuroscience, implantable medical devices, and regulated innovation.
Science Significance
From a scientific standpoint, the Orion System represents a breakthrough in targeted neurostimulation, bypassing damaged ocular pathways and directly stimulating the visual cortex of the brain to generate perceptual visual signals. Five-year clinical data demonstrating sustained device performance without reported malfunctions underscore the robustness of the implant’s design and neuro-electronic interface. The ability of implanted subjects to continue using the system independently in real-world environments highlights meaningful functional integration, a critical benchmark in neuroprosthetic research. These findings advance the broader field of artificial vision and brain–computer interface science, supporting the feasibility of long-term cortical stimulation for sensory restoration.
Regulatory Significance
Regulatorily, the Orion System is progressing within a structured Early Feasibility Study framework supported by the National Institutes of Health, reflecting compliance with FDA expectations for investigational implantable medical devices. The extension of the study to six years demonstrates a commitment to long-term safety monitoring and performance validation, key requirements for advancing toward pivotal trials. Cortigent’s stated intent to use EFS learnings to guide a future pivotal study aligns with Good Clinical Practice principles, risk mitigation strategies, and evolving FDA guidance for complex neurotechnology platforms.
Business Significance
Advertisement
From a business perspective, the presentation strengthens Vivani Medical’s diversified innovation portfolio, which spans both implantable drug delivery systems and advanced neurostimulation devices. Demonstrating durable clinical performance enhances the commercial credibility of the Orion platform, supporting future investment, strategic partnerships, and potential licensing discussions. For Cortigent, positive long-term data de-risks development and positions the company favorably within the high-growth neurotechnology and implantable device market, where evidence of durability and usability is critical for payer, provider, and partner confidence.
Patients’ Significance
For patients, particularly those who are profoundly blind due to irreversible ocular damage, Orion offers a potential pathway toward restored visual perception and improved independence. The absence of device failures over multiple years and continued at-home use suggest a therapy that could deliver sustained quality-of-life benefits rather than short-lived experimental gains. The technology addresses a significant unmet medical need, with tens of thousands of individuals in the U.S. alone lacking viable restorative options, underscoring the human impact of successful neuroprosthetic innovation.
Policy Significance
At the policy level, the Orion program reflects growing public and institutional support for responsible development of implantable neurotechnologies. NIH funding, extended feasibility studies, and transparent reporting of long-term outcomes align with policy goals to ensure patient safety, ethical oversight, and evidence-based adoption of advanced medical devices. As governments and regulators worldwide evaluate frameworks for brain–computer interfaces and neural implants, programs like Orion provide real-world clinical evidence that can inform future regulatory standards and reimbursement pathways.
Overall, Cortigent’s presentation of Orion System clinical data marks an important milestone in the evolution of implantable neurostimulation technologies, combining scientific rigor, regulatory discipline, and patient-centered outcomes. With sustained safety and functional performance demonstrated over five years, the Orion program advances the conversation around long-term viability of brain implants and reinforces Vivani Medical’s role in shaping the future of regulated neurotechnology innovation.
Source: Vivani Medical, Inc. press release
